Form 6K GSK plc For: 5 March
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
GSK plc (GSK)
Find here information about GSK share price. You can find more details about GlaxoSmithKline share price by going to one of the sections listed on this page such as historical data, price charts, GSK shares technical analysis and more.
2,043.00
-33.00(-1.59%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,028.00
2,080.36
52 wk Range
1,242.50
2,282.00
GSK is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2,028.002,080.36
52 wk Range
1,242.502,282.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.18%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GSK Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
2,032.25
Downside
-0.53%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
- Glaxosmithkline receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K GSK plc For: 4 March
- Investing.com
- Form 6K GSK plc For: 27 February
- Investing.com
- Form 6K GSK plc DRC For: 3 March
- Investing.com
- Form 6K GSK plc For: 5 March
- Investing.com
- Form 6K GSK plc For: 4 March
- Investing.com
- Form 6K GSK plc DRC For: 3 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
GSK plc Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Compare GSK to Peers and Sector
Metrics to compare | GSK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGSKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.6x | 22.7x | −0.5x | |
PEG Ratio | 0.12 | 0.41 | 0.00 | |
Price/Book | 5.1x | 4.7x | 2.6x | |
Price / LTM Sales | 2.5x | 3.5x | 3.2x | |
Upside (Analyst Target) | −7.5% | 16.8% | 51.4% | |
Fair Value Upside | Unlock | 15.4% | 8.5% | Unlock |
Analyst Ratings
5 Buy
13 Hold
4 Sell
Ratings:
22 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 2,032.25
(-0.53% Downside)
Earnings
Latest Release
Feb 04, 2026
EPS / Forecast
0.255 / 0.238
Revenue / Forecast
8.62B / 8.48B
People Also Watch
FAQ
What Is the GSK plc (GSK) Share Price Today?
The GSK plc stock price today is 2,043.00 GBP.
What Stock Exchange Does GSK plc (GSK) Trade On?
GSK plc is listed and trades on the London Stock Exchange.
What Is the Ticker (Stock Symbol) for GSK plc?
The stock symbol (also called a 'ticker') for GSK plc is "GSK."
Does GSK plc Pay Dividends? What’s The Current GSK Dividend Yield?
Yes, GSK Pays Dividends to its Shareholders. The current GSK plc dividend yield is 3.18%.
What Is the Current GSK plc Market Cap?
As of today, GSK plc market cap is 81.81B GBP.
What Is GSK plc's (GSK) Earnings Per Share (TTM)?
The GSK plc EPS is currently 1.39 (Trailing Twelve Months).
When Is the Next GSK plc Earnings Date?
GSK plc's next earnings report will be released on 29/04/2026.
Is GSK a Buy or Sell From a Technical Analyst Perspective?
Based on today's GSK plc moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has GSK plc Stock Split?
GSK plc has split 1 times. (See the GSK stock split history page for full effective split date and price information.)
How Many Employees Does GSK plc Have?
GSK plc has 68629 employees.
What is the current trading status of GSK plc (GSK)?
As of 06/03/2026, GSK plc (GSK) is trading at a price of 2,043.00 GBP, with a previous close of 2,076.00 GBP. The stock has fluctuated within a day range of 2,028.00 GBP to 2,080.36 GBP, while its 52-week range spans from 1,242.50 GBP to 2,282.00 GBP.
What Is GSK plc (GSK) Price Target According to Analysts?
The average 12-month price target for GSK plc is 2,032.25 GBP, with a high estimate of 2750 GBP and a low estimate of 1455 GBP. 5 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an -0.53% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.